Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer
VRPXDelisted Stock | USD 0.25 0.04 19.05% |
Slightly above 55% of Virpax Pharmaceuticals' investors are presently thinking to get in. The analysis of overall sentiment of trading Virpax Pharmaceuticals pink sheet suggests that some investors are interested at this time. Virpax Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Virpax Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Virpax |
GLEN ALLEN, Va., Nov. 05, 2024 -- Adial Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment of Vinay Shah as the Companys Chief Financial Officer, effective November 16, 2024. Vinay Shah is an accomplished Chief Financial Officer with over 25 years of experience in the pharmaceutical, biophar
Read at finance.yahoo.com
![]() |
Virpax Pharmaceuticals Fundamental Analysis
We analyze Virpax Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Virpax Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Virpax Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Debt To Equity
Debt To Equity Comparative Analysis
Virpax Pharmaceuticals is currently under evaluation in debt to equity category among its peers. Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Virpax Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Virpax Pharmaceuticals pink sheet to make a market-neutral strategy. Peer analysis of Virpax Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Virpax Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Virpax Pharmaceuticals Related Equities
PALI | Palisade Bio | 6.58 | ||||
QNRX | Quoin Pharmaceuticals | 5.08 | ||||
VRAX | Virax Biolabs | 2.00 | ||||
KPRX | Kiora Pharmaceuticals | 0.33 | ||||
PRAX | Praxis Precision | 1.98 | ||||
KTTA | Pasithea Therapeutics | 2.13 | ||||
LGVN | Longeveron LLC | 2.17 | ||||
RNXT | RenovoRx | 3.25 | ||||
NTRB | Nutriband | 4.36 | ||||
REVB | Revelation Biosciences | 6.18 | ||||
BDRX | Biodexa Pharmaceticals | 17.27 |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in Virpax Pink Sheet
If you are still planning to invest in Virpax Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Virpax Pharmaceuticals' history and understand the potential risks before investing.
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |